The Life Sciences team advised Generate:Biomedicines on the closing of its $273 million Series C. The financing round attracted many new investors including Amgen; NVentures, NVIDIA’s venture capital arm; MAPS Capital (Mirae Asset Group); and Pictet Alternative Advisors. Additionally, company founder, Flagship Pioneering, and every Series B investor, including a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA); Fidelity Management & Research Company; funds and accounts advised by T. Rowe Price Associates, Inc.; ARCH Venture Partners; and March Capital, participated in the round.
Generate:Biomedicines has raised nearly $700 million in equity financing since 2020. The company has a robust pipeline of 17 programs in preclinical and clinical development across oncology, immunology, and infectious disease. Generate:Biomedicines will leverage Series C funding to further its pipeline, including filing multiple INDs in 2024 and initiating multiple clinical trials annually thereafter.
The Goodwin team was led by Stuart Cable, Joseph Theis, Robert Dzialo, Lauren Visek and Ryan Donahoe.
For additional details on the funding round, please read the press release.